Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
Tag: orphan drugs
G-BA assessment of orphan drug gene therapies, Zolgensma and Libmeldy
The gene therapies Zolgensma and Libmeldy, both, are targeting very rare, severe, genetic diseases in children. The G-BA has now assessed the